כסף מזומן למניה ARS Corp (SPRY)

ARS Pharmaceuticals employs algorithmic methods to develop innovative nasal sprays, although final trials require medical supervision. The capital expenditure minimization strategy relies on outsourcing production to third-party contractors. Meanwhile, building inventories of finished goods mitigates the risks of vendor dependency. Cash per share demonstrates financial stability, where 1.39 represents the latest level value.
פילוחים אנליטיים של חברת ARS Pharmaceuticals

Cash per share measures the volume of a company's liquid reserves per security, allowing for an assessment of the assets' intrinsic value and the level of financial stability. The current cash per share for ARS Pharmaceuticals (SPRY) is 1.39, which, combined with the monopoly position of the drug neffy in the anaphylaxis treatment market, confirms the high capital reliability of SPRY.